Credits: Canva
The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.
It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.
The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.
TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."
Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.
While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.
Credit: iStock
The currently used breast cancer screening referral criteria at the NHS are missing up to 95% of women under 50 who are at higher risk of developing breast cancer in the next decade, according to a new study.
Published in the British Journal of Cancer, the study found that a more comprehensive, personalized risk assessment could identify 8 times as many women at risk as the current NICE guidelines.
In England, women at higher risk of breast cancer are typically identified after being referred by their GP based on family history, following criteria set by the National Institute for Health and Care Excellence (NICE), under the NHS.
The researchers from the University of Cambridge and The Institute of Cancer Research, London, analyzed data from 1,258 women under the age of 50.
They found that the criteria would refer only 1.4% of women for specialist assessment and identify just 4.4% of women who went on to develop breast cancer within the next 10 years.
The researchers then evaluated BOADICEA, a multifactorial risk model that combines:
Using this model, 26.5% of women were classified as having above-average risk and referred for further assessment. This approach identified 34.8% of women who developed breast cancer within the following 10 years—around eight times more than the current NICE criteria.
One major reason for the gap is that 73% of women under 50 who developed breast cancer had no family history of the disease, making them unlikely to qualify for referral under existing guidelines.
"We need to get better at identifying women at highest risk of breast cancer so that we can intervene early, when there are more options for treating, or even preventing, their disease," said Dr Juliet Usher-Smith from the Department of Public Health and Primary Care at the University of Cambridge.
A second study by the same research team found strong public support for proactive breast cancer risk assessments for women aged 30 to 49, instead of relying on women to seek GP referrals because of family history.
They found that women preferred:
Dr Sowmiya Moorthie, Senior Strategic Evidence Manager at Cancer Research UK, said broader risk assessment could help more women receive personalized care. However, she noted that further research is needed to understand the impact on NHS staffing, equipment, and patient experience, while ensuring any new approach remains accessible and equitable.
She also emphasized that maintaining a healthy weight, limiting alcohol intake, and seeking medical advice for any unusual breast changes remain important ways to reduce risk and improve outcomes through early diagnosis.
Breast cancer is the most common cancer worldwide, with steady increases in incidence over the last few decades. It accounts for around one in four cases of cancer and 15 per cent of cancer deaths in women, and is one of the leading causes of death in women under 50.
Breast cancer is the most common cancer in the UK, with around 59,400 new cases diagnosed annually and roughly 11,200 deaths each year. About one in seven women in the UK develops the disease in their lifetime, though survival rates are high, with nearly 90% surviving for five years or more.
Credit: iStock
Health officials in New York have reported at least three suspected cases of tularemia, a rare bacterial illness also known as rabbit fever.
The disease can spread through the bite of infected ticks or deer flies, or through contact with infected animals, particularly rabbits and rodents.
The Suffolk County Department of Health said laboratory testing is required to confirm the suspected cases, a process that may take several weeks.
"Confirmation of a tularemia diagnosis requires a combination of laboratory testing and fulfillment of specific clinical or epidemiologic criteria," the department told ABC 7, New York.
"The laboratory testing to confirm a tularemia diagnosis may take several weeks."
Tularemia is most commonly reported between May and September, according to the US Centers for Disease Control and Prevention (CDC).
Fewer than 200 cases are reported annually in the US, based on CDC data from 2019 to 2023. Although still rare, reported cases have been increasing.
In Suffolk County, Long Island:
Tularemia is a rare but potentially serious bacterial infection caused by Francisella tularensis, according to the CDC.
The disease can affect the skin, lymph nodes, eyes, throat, lungs, and other organs depending on how the bacteria enter the body.
People can become infected through:
According to the CDC, the case fatality rate is typically below 2%, though it can be higher depending on the bacterial strain and type of illness.
There are six main forms of tularemia:
Symptoms vary depending on the type of infection but commonly include:
Because tularemia is rare, it can be difficult to diagnose, and its symptoms often resemble more common illnesses.
Tularemia is highly treatable with antibiotics when diagnosed promptly.
The CDC noted that a vaccine previously used to protect laboratory workers is currently under review by the US Food and Drug Administration and is not generally available.
The CDC recommends the following precautions:
Credit: AI
The Philippines has launched a fresh measles-rubella vaccination campaign in Eastern Visayas, aiming to vaccinate more than 445,000 children aged six to 59 months.
The intensified Measles-Rubella Supplemental Immunization Activity (MR-SIA) will run from August 10 to 28, with support from local governments, schools, community health workers and barangay officials.
The campaign comes as the country continues to recover from years of declining routine childhood immunisation, which left thousands of children at risk to vaccine-preventable diseases.
"Knowing that our past accomplishments in the country are not that high, the Department of Health decided to have an additional layer of protection for our children by coming up with the Measles-Rubella Immunization Activity," said Dr Exuperia Sabalberino, Regional Director of the Department of Health Eastern Visayas Center for Health Development.
According to the Department of Health (DOH), Leyte accounts for the largest target population, with more than 152,000 eligible children, while Biliran has the smallest.
Children under five years of age will be offered the vaccine regardless of their previous vaccination status if they fall within the campaign's eligibility criteria.
Health authorities have been race to close immunity gaps and prevent new outbreaks of the highly contagious disease.
The latest push follows concerns over low routine immunisation coverage in several Philippine regions. During the 2023 MR-SIA campaign, Eastern Visayas achieved only 72.6% vaccination coverage, well below the level needed to maintain herd immunity.
Health officials warn that insufficient coverage increases the risk of measles and rubella outbreaks. "Vaccination is an extra layer of protection and also prevents outbreaks, as measles and rubella are highly contagious because one confirmed case can affect 12 to 18 people, especially those who are vulnerable and immunocompromised," said Chiradee R. Claridad, DOH-8 National Immunization Program Coordinator.
Also read: US Measles Cases Reach 2,371; RFK Jr Takes U-Turn, Urges Families to Vaccinate Kids
Measles is among the world's most infectious viral diseases, spreading through respiratory droplets when an infected person coughs or sneezes.
It can lead to serious complications including pneumonia, brain inflammation, blindness and death, particularly in young children. Rubella is generally milder but can cause severe birth defects if a pregnant woman becomes infected.
The Philippines has experienced several major measles outbreaks in recent years, including the nationwide resurgence in 2019 and the Bangsamoro outbreak in 2024, both linked to poor vaccination coverage.
The Philippines has already made progress in recent months. Last month, the DOH announced that over one million children in Metro Manila had been vaccinated, achieving 87.1% coverage under the measles-rubella campaign.
The latest campaign also comes after measles gained global attention after several countries, including the United States and parts of Europe, reported outbreaks this year driven by falling childhood vaccination rates.
The United States has reported 2,371 in 2026m according to the latest data from the Centers for Disease Control and Prevention (CDC). Among these cases:
© 2024 Bennett, Coleman & Company Limited